Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

ompetition, and others stated in risk factors contained in our SEC filings.  We cannot assure that we have identified all risks or that others may emerge which we do not anticipate.  You should not place undue reliance on forward-looking statements.  Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

Galectin Therapeutics and its associated logo is a trademark of Galectin Therapeutics Inc.

 Condensed Consolidated Statements of OperationsThree Months
EndedDecember 31,Twelve MonthsEndedDecember 31,2012201120122011(in thousands, except per share data)

(unaudited)Operating expenses:  Research and development

$1,002

$862

$4,527

$3,552  General and administrative

1,380

2,510

5,372

6,857  Total operating expenses

2,382

3,372

9,899

10,409Total operating loss

(2,382)

(3,372)

(9,899)

(10,409)Other income and (expense):  Interest income

6

4

24

18  Change in fair value of warrant liabilities

-

-

-

(524)  Other income

-

-

200

-Total other income (expense)

6

4

224

(506)Net loss

$(2,376)

$(3,368)

$(9,675)

$(10,915)Preferred stock dividends and accretion costs

(332)

(350)

(1,206)

(1,798)Net loss applicable to common stock

$(2,708)

$(3,718)

$(10,881)

$(12,713)Basic and diluted net loss per share

$  (0.17)

$  (0.29)

$  (0.72)

$  (1.06)Shares used in computing basic and diluted net loss per share

15,966

12,846

15,131

11,986 Condensed Consolidated Balance She
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Biofertilizers stimulate microbial activities in soil. These microorganisms ... the activities in the soil or in the rhizosphere. ... stress on reducing environmental pollution and on reducing the ... segments the bio fertilizers market with analysis and forecasting ...
(Date:1/22/2015)... today announces the firm brokered a long-term lease totaling 202,492 ... company, at Two Ledgemont Center in Lexington, Massachusetts ... and Brian Cohen , senior vice president, represented Shire ... Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... Protocol Networks brings independent technology consulting to ... independent consultants, Protocol Networks has recently announced its expansion ... years, his company has attracted several clients in The ... well as others. With the success of these engagements, ...
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
Breaking Biology Technology:Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 2Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 3Biofertilizers Market Expected to Reach $1,649.7 Million by 2019 - New Report By MarketsandMarkets 4Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2
... 26, 2011 , Veeva Systems ... top 20 pharmaceutical companies, is replacing its legacy,on-premise ... the UK. Daiichi Sankyo will deploy Veeva CRM ... including integrated healthcare,specialty care, medical liaison scientists, and ...
... At an event at the University City Science ... U.S. Representatives Chaka Fattah (D-PA), Allyson Schwartz (D-PA) and ... that provides tax incentives for small and mid-sized businesses ... a targeted basis. The Life Sciences Jobs and ...
... Robert Ettinger, the founder of the cryonics movement and ... home in Clinton Township, Michigan, and has been frozen at ... temperatures after death in the hope that future technology will ... Mr. Ettinger wrote The Prospect of Immortality ...
Cached Biology Technology:Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 2Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 3Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom 4Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 2Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 3Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 4Coalition Applauds Introduction of Life Sciences Jobs and Investment Act 5Founder of Cryonics Movement Dies, is Frozen at Cryonics Institute 2
(Date:1/22/2015)... EyeLock, Inc. , a market leader of iris-based identity authentication ... to the new role of Senior Vice President of Mobile ... mobile platforms and wearable solutions for EyeLock,s technologies. Gerber brings ... semiconductor industry to his role at EyeLock, with expertise in ...
(Date:12/22/2014)...  The 2014 Holiday Season may be the brightest ever ... that the long anticipated floodgates for consumer biometrics may ... smart phones, tablets, and wearable mobile devices that incorporate ... users with nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... the "Samsung Galaxy S5 - Home Button Synaptics ... http://photos.prnewswire.com/prnh/20130307/600769 ... iPhone 5S, Samsung introduces for the first time a ...
Breaking Biology News(10 mins):EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... Viral diseases are still one of the biggest challenges ... co-evolution with humans, their ability to harness the biology of ... difficult to target with medical treatment. Scientists at the ... from the University of Colorado, have shown for the first ...
... The changes to the publication requirements of new ... XVIII International Botanical Congress in Melbourne in July 2011 ... To address practical questions arising from the Congress decisions, the ... a series of seven exemplar papers, one each day for ...
... 2011  The Evermedia Group, Inc. (Pinksheets: EVRM) would like ... colleagues: First and foremost, I want to thank our ... CEO to The Evermedia Group, advancing the interests of ... Biometrics (EBC).  I have been fortunate to work with ...
Cached Biology News:Hepatitis C virus hijacks liver microRNA 2Brave new world 2Brave new world 3The Evermedia Group 2011 Year in Review 2The Evermedia Group 2011 Year in Review 3The Evermedia Group 2011 Year in Review 4
Request Info...
Anti-ZFP200 Family: Zinc Finger Peptide Sequence: CGKSFNHKTNLNKHER...
Donor feline serum and plasma...
Collected from sexually mature, mixed sex, mixed breed cats. Physiochemical constituents are measured to ensure lot-to-lot consistency....
Biology Products: